Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that Dr. Mark Pykett, President and CEO of Navidea, will present a business and program update during the 2013 Biotech Showcase Conference to be held at the Parc 55 Wyndham-Union Square in San Francisco, CA. Dr. Pykett will speak on Monday, January 7, 2013 at 10:00 AM PST. Investors and the public are invited to listen to a live webcast of the presentation at
. Following the conference, the webcast will be archived for approximately 30 days.
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a biopharmaceutical company focused on the development and commercialization of precision diagnostics and radiopharmaceutical agents. Navidea is actively developing four radiopharmaceutical agent platforms – Lymphoseek
, NAV4694, NAV5001 and RIGScan
– to help identify the sites and pathways of undetected disease and enable better diagnostic accuracy, clinical decision-making and, ultimately, patient care. Navidea’s strategy is to deliver superior growth and shareholder return by bringing to market novel radiopharmaceutical agents and advancing the Company’s pipeline through selective acquisitions, global partnering and commercialization efforts. For more information, please visit
About Biotech Showcase 2013
Biotech Showcase is an investor and partnering conference devoted to providing private and public biotechnology and life sciences companies an opportunity to present to, and meet with, investors and pharmaceutical executives during the course of one of the industry’s largest annual healthcare investor conferences. Now in its fifth year, Biotech Showcase is expected to attract upwards of 1,500 attendees. Biotech Showcase is co-produced by Demy-Colton Life Science Advisors and EBD Group. Demy-Colton Life Science Advisors is focused exclusively on facilitating the growth of the life science industry. EBD Group is the leading partnering firm for the global life science industry.